5th Annual MarketsAndMarkets Next-Gen Immuno-Oncology Conference MarketsandMarkets

23rd-24th June 2022

Hyatt Regency Boston/Cambridge

Our 5th Annual MarketsandMarkets Next Gen Immuno-Oncology Conference to be held on 23rd-24th, June 2022, in Boston, would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors.

This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development and personalized immunotherapy. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions.

With more than 20 speakers across the world from pharma, bio-pharma and biotech companies, the congress will discuss the latest updates in development of ADC’s, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors and Cellular Therapy  

CO-LOCATED CONFERENCES

3rd Annual MarketsandMarkets Single-Cell Analysis Conference

WHAT TO EXPECT

  • Updates in development of ADC’s and Bispecific Ab’s
  • Immune Checkpoint Inhibitors and Combinations
  • Preclinical and Translational Immuno-Oncology Developments (Preclinical models for Immune checkpoint modulators)
  • Biomarkers and Personalized Medicine in IO
  • CAR-T Cell therapy, TCR Based-Cell Therapy
  • Tumor microenvironment and Oncolytic Viruses

CSO, Director, VP, Head, Senior Investigator, Manager, Principal Scientist, Team Leader, Group Leaders, Professors, Assistant Professors, Research fellows, PhDs working on

  • Monoclonal and Bispecific Antibodies
  • Cell Therapy
  • Immune Checkpoint Inhibitors

  • Exclusive conference to learn about antibodies, cellular therapy and immune-checkpoint research under one roof
  • Find out new case studies of immune-oncology projects in development
  • Contribute to interactive roundtables with your peers to deliberate key topics most relevant to you
  • Explore the latest platforms and technologies on the market for development
  • Discuss the best tool for your research in immune-oncology
  • Share your work and achievements with your industry peers in the Poster Session

CONFERENCE AGENDA

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening remarks from the Chairman

08:55 - 09:00

New Antibody Formats & Adoptive Cell Therapy

Role of Biospecimen science in Clinical Immuno-Oncology Biomarkers: Lessons learned

Lokesh Agrawal

Lokesh Agrawal, Program Director Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (NIH)

09:00 - 09:30

Methods for Epigenetic Analysis for Immunological and Oncological Related Therapies.

Matthew Poulin

Matthew Poulin, Scientific Director, EpigenDx

09:30 - 10:30

One Size Does Not Fit All: Tailor Made Precision Diagnostics from Sample to Insight

Jennifer Elliott

Jennifer Elliott , Senior Director, Oncology & Precision Medicine , Qiagen

10:00 - 10:30

Morning Refreshments and Poster Presentations | One-to-One Networking Meetings

10:30 - 11:15

In vivo modeling of CD3 bispecific efficacy and toxicity

Alison Crawford

Alison Crawford, Associate Director of Immuno-oncology, Regeneron Pharmaceuticals, Inc.

11:15 - 11:45

Enhanced Biomarker Discovery and Validation Using TMT® Proteomics

Ian Pike

Ian Pike, Chief Scientific Officer, Proteome Sciences PLC

11:45 - 12:15

Drugging the Undruggable: Nuclear-Specific Beta Catenin Small Molecule Degrader

Sam Shrivastava

Sam Shrivastava, CEO, Founder, Asha Therapeutics

12:15 - 12:45

From Cold to Hot: Novel Therapeutic Modulation of the Tumor Microenvironment

Bradlee Heckmann

Bradlee Heckmann, CSO, Asha Therapeutics

12:45 - 13:15

Lunch and Poster Presentations | One-to-One Networking Meetings

13:15 - 14:15

Presentation by Angle Plc.

14:15 - 14:45

Cancer Immunotherapy: accelerating preclinical drug candidate selection using the full advanced human immune system mouse models

Sebastien Tabruyn

Sebastien Tabruyn, Chief Scientific Officer, Transcure Bioservices

14:45 - 15:15

Immune Checkpoint inhibitors in Resectable Gastroesophageal Cancers-a Window of Opportunity

Sarbajit Mukherjee

Sarbajit Mukherjee , Assistant Professor, Oncology Roswell Park Comprehensive Cancer Center

15:15 - 15:45

Afternoon Refreshments and Poster Presentations | One-to-One Networking Meetings

15:45 - 16:30

Panel Discussion: Future directions in cell therapy. Beyond CD19 CARs?

16:30 - 17:00

Creating therapies using the natural biology of T cells to treat patientswith solid tumors.

Paul Lammers

Paul Lammers, President & CEO, Triumvira Immunologics

17:00 - 17:30

NK Cell targeted therapy in IO

17:30 - 18:00

End of Day 1 followed by Drinks, Reception and Networking

Closing remarks from the Chairman - End of Day 1

18:00 - 18:15

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening remarks from the Chairman

08:55 - 09:00

New Immune Checkpoints, Biomarker and Tumour Microenvironment

Keynote Presentation - SUPLEXA Therapeutic Cells : Individualized blood-derived adoptive cellular therapy to treat cancer!

Frank Borriello

Frank Borriello, CEO, Alloplex Biotherapeutics

09:00 - 09:30

Engineering a Rational Approach to Personalized Oncology Therapies

Colin Brenan

Colin Brenan, CEO, Kibur Medical Inc.

09:30 - 10:00

Addressing Tumor Heterogeneity with non-viral Oncolytic agents - an unsolved issue in Cancer Immunotherapy

Oystein Rekdal

Oystein Rekdal, CEO, Lytix Biopharma

10:00 - 10:30

Morning Refreshments and Poster Presentations | One-to-One Networking Meetings

10:30 - 11:15

New data on the usefulness of Immunoscore IC® as an immune biomarker in metastatic NSCLC and CRC

Jerome Galon

Jerome Galon, Chief Scientific Officer of Immuno-Oncology , HalioDx, now part of Veracyte

11:15 - 11:45

Autonomous IL-36R Signaling Reprograms Neutrophils into Potent Anti-tumor Effectors Cells

Rajkumar Noubade

Rajkumar Noubade, Director, Gilead Sciences

11:45 - 12:15

ICI with Chemotherapy: why and how?

Stefan Glueck

Stefan Glueck, Ex- Vice President, Global Head Franchise Oncology, Regeneron

12:15 - 12:45

Attivare Tx: An off-the-shelf solution that generates a personalized immune response

Jessica McDonough

Jessica McDonough, Co-Founder, Attivare Therapeutics

12:45 - 13:15

Lunch and Poster Presentations | One-to-One Networking Meetings

13:15 - 14:15

Soluble TNFα blockade sensitizes HER2-positive breast cancer to trastuzumab subverting immunosuppression

Roxana Schillaci

Roxana Schillaci, Principal Researcher, Argentina National Council of Scientific Research

14:15 - 14:45

Individualized neoantigen directed immunotherapy requires Individualized translational biomarkers.

Matt Davis

Matt Davis, Director, Molecular Biology & Sequencing, Gritstone Oncology, Inc.

14:45 - 15:15

Closing remarks from the Chairman - End of Day 2

Stefan Glueck

Stefan Glueck, Ex- Vice President, Global Head Franchise Oncology, Regeneron

15:15 - 15:25

SPEAKERS

Lokesh Agrawal

Lokesh Agrawal

Program Director, Biorepositories and Biospecimen Research Branch (BBRB), , NIH

Colin Brenan

Colin Brenan

CEO, Kibur Medical Inc.

Bradlee Heckmann

Bradlee Heckmann

CSO, Asha Therapeutics

Ian Pike

Ian Pike

Chief Scientific Officer, Proteome Sciences PLC

Jessica McDonough

Jessica McDonough

Co-Founder, Attivare Therapeutics

Roxana Schillaci

Roxana Schillaci

Principal Researcher, Argentina National Council of Scientific Research

Sam Shrivastava

Sam Shrivastava

CEO, Founder, Asha Therapeutics

Jennifer Elliott

Jennifer Elliott

Senior Director, Oncology & Precision Medicine , Qiagen

Rajkumar Noubade

Rajkumar Noubade

Director, Gilead Sciences

Sarbajit Mukherjee

Sarbajit Mukherjee

Assistant Professor, Oncology Roswell Park Comprehensive Cancer Center

Shahram Salek-Ardakani

Shahram Salek-Ardakani

Chief Scientific Officer, Janux Therapeutics

Paul Lammers

Paul Lammers

President & CEO, Triumvira Immunologics

Alison Crawford

Alison Crawford

Associate Director of Immuno-oncology, Regeneron Pharmaceuticals, Inc.

John Rossi

John Rossi

Vice President, Head, Translational Medicine, , Syncopation Lifesciences

Stefan Glueck

Stefan Glueck

Ex- Vice President, Global Head Franchise Oncology, Regeneron

Sebastien Tabruyn

Sebastien Tabruyn

Chief Scientific Officer, Transcure Bioservices

Jerome Galon

Jerome Galon

Chief Scientific Officer of Immuno-Oncology , HalioDx, now part of Veracyte

Matthew Poulin

Matthew Poulin

Scientific Director, EpigenDx

Oystein Rekdal

Oystein Rekdal

CEO, Lytix Biopharma

Matt Davis

Matt Davis

Director, Molecular Biology & Sequencing, Gritstone Oncology, Inc.

ENQUIRE NOW

SPONSORS

PARTNERS

LOCATION

Venue

Hyatt Regency Boston/Cambridge

PAST EVENT GALLERY